Akums Drugs Pharmaceuticals Ltd vs Ambalal Sarabhai Enterprises Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Akums Drugs & Pharmaceuticals Ltd is ₹ 552.5 as of 06 May 15:30 . The P/E Ratio of Akums Drugs & Pharmaceuticals Ltd changed from 21.5 on March 2025 to 21.5 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 years The Market Cap of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 7469 crore on March 2025 to ₹ 7469 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 years The revenue of Akums Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 1193 crore as compare to the Sep '25 revenue of ₹ 1049 crore. This represent the growth of 13.72% The revenue of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 54.76 crore as compare to the Sep '25 revenue of ₹ 46.07 crore. This represent the growth of 18.86% The ebitda of Akums Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 162.96 crore as compare to the Sep '25 ebitda of ₹ 126.84 crore. This represent the growth of 28.48% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 6.02 crore as compare to the Sep '25 ebitda of ₹ 1.98 crore. This represent the growth of 204.04% The net profit of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 61.21 crore to ₹ 67.67 crore over 7 quarters. This represents a CAGR of 5.90% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 3.64 crore over 7 quarters. This represents a CAGR of 281.21% The Dividend Payout of Akums Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Akums Drugs & Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC. Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients.
Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services.
Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation.

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.

FAQs for the comparison of Akums Drugs & Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd

Which company has a larger market capitalization, Akums Drugs & Pharmaceuticals Ltd or Ambalal Sarabhai Enterprises Ltd?

Market cap of Akums Drugs & Pharmaceuticals Ltd is 8,691 Cr while Market cap of Ambalal Sarabhai Enterprises Ltd is 240 Cr

What are the key factors driving the stock performance of Akums Drugs & Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd?

The stock performance of Akums Drugs & Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Akums Drugs & Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd?

As of May 6, 2026, the Akums Drugs & Pharmaceuticals Ltd stock price is INR ₹552.2. On the other hand, Ambalal Sarabhai Enterprises Ltd stock price is INR ₹31.33.

How do dividend payouts of Akums Drugs & Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd compare?

To compare the dividend payouts of Akums Drugs & Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.